4.6 Article

Mechanisms of immune evasion in breast cancer

期刊

BMC CANCER
卷 18, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/s12885-018-4441-3

关键词

Immunity; Immunotherapy; Lymphocytes; Cytokines; Dendritic cells; PD-1; Regulatory T cells; Myeloid derived suppressor cells

类别

资金

  1. National Cancer Institute of the National Institutes of Health [R21CA184469, R21CA199544]
  2. NATIONAL CANCER INSTITUTE [R21CA199544, R21CA184469] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Tumors develop multiple mechanisms of immune evasion as they progress, with some cancer types being inherently better at 'hiding' than others. With an increased understanding of tumor immune surveillance, immunotherapy has emerged as a promising treatment strategy for breast cancer, despite historically being thought of as an immunologically silent neoplasm. Some types of cancer, such as melanoma, bladder, and renal cell carcinoma, have demonstrated a durable response to immunotherapeutic intervention, however, breast neoplasms have not shown the same efficacy. The causes of breast cancer's immune silence derive from mechanisms that diminish immune recognition and others that promote strong immunosuppression. It is the mechanisms of immune evasion in breast cancers that are poorly defined. Thus, further characterization is critical for the development of better therapies. This brief review will seek to provide insight into the possible causes of weak immunogenicity and immune suppression mediated by breast cancers and highlight current immunotherapies being used to restore immune responses to breast cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据